Oncolys BioPharma Inc. provided earning guidance for the Year Ending December 31, 2022. The company expects Net sales to be JPY 1,000 million, Operating loss to be JPY 1,600 million, loss to be JPY 1,600 million, Basic loss per share to be JPY 94.59.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
698 JPY | 0.00% | +3.71% | +23.10% |
1st Jan change | Capi. | |
---|---|---|
+23.10% | 92.59M | |
+0.59% | 92.38B | |
-3.03% | 37.9B | |
-10.46% | 33.73B | |
+74.71% | 27.98B | |
-13.39% | 15.86B | |
-1.08% | 13.97B | |
-11.15% | 11.67B | |
+169.04% | 10.17B | |
-50.19% | 10.04B |
- Stock Market
- Equities
- 4588 Stock
- News Oncolys BioPharma Inc.
- Oncolys Biopharma Inc. Provides Earning Guidance for the Year Ending December 31, 2022